Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy

被引:162
作者
Donadio, JV
Bergstralh, EJ
Grande, JP
Rademcher, DM
机构
[1] Mayo Clin & Mayo Fdn, Div Nephrol, Dept Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Div Anat Pathol, Dept Lab Med & Pathol, Rochester, MN 55905 USA
关键词
IgA nephropathy; prognosis; proteinuria;
D O I
10.1093/ndt/17.7.1197
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Proteinuria (UP) > 1.0 g/24 h at diagnosis is a well-known indicator of progressive renal disease in patients with IgA nephropathy (IgAN), To determine if persistent UP is a more sensitive marker for later progression of IgAN, the hypothesis was tested that the prior level and trend (slope) in UP for 1 year was better at predicting later end-stage renal disease (ESRD) (dialysis or transplant) than a current 24-h UP, serum creatinine (SC), SC slope., hypertension, or total glomerular histopathological score on index renal biopsy in an observational study of 154 high-risk patients enrolled in two clinical trials (IgAN 1, IgAN 2). Methods. Measurements of 24-h UP and SC were made at time 0, 6 weeks, 6 months and 1x year in all patients, who were then followed for an additional 5.76 years and 1.63 years in the two studies. respectively. The Cox proportional hazards model was used t Results. Adjusting only for randomized treatment, nearly all UP variables (number of high readings, 1-year level, slopes), SC at I year, and SC trends (slopes) over the prior year were significantly associated with subsequent ESRD (all P values <0.05) in both studies. However, among the UP variables, the 1-year readings had the strongest association with ESRD in IgAN I (hazard ratio (HR), 95% CI, for a 1g increase: 1.5, 1.2,1.9), and the second strongest association (similar to UP trends) in IgAN 2 (1.4, 1.2,1.6). Males had lower rates of ESRD in both studies (IgAN I HR: 0.5, 0.2,1.2, P=0.11; IgAN 21 HR: 0.2, 0.1,0.6, P=0.002). In the multivariate analyses that examined all clinical and histological variables, 1-year levels of 24-h UP and SC, and female gender were independently associated with subsequent ESRD. Conclusion. In a high-risk patient with IgAN, the current 24-h UP and SC measurements are as good predictors of subsequent ESRD as UP and SC trends and levels over the prior year. Additionally, it appears that females have poorer outcomes than males.
引用
收藏
页码:1197 / 1203
页数:7
相关论文
共 23 条
[1]  
BANNISTER KM, 1995, CONTRIB NEPHROL, V111, P184
[2]  
BENNETT WM, 1989, CLIN NEPHROL, V31, P128
[3]   LONG-TERM BENEFITS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR THERAPY IN PATIENTS WITH SEVERE IMMUNOGLOBULIN A NEPHROPATHY - A COMPARISON TO PATIENTS RECEIVING TREATMENT WITH OTHER ANTIHYPERTENSIVE AGENTS AND TO PATIENTS RECEIVING NO THERAPY [J].
CATTRAN, DC ;
GREENWOOD, C ;
RITCHIE, S .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 23 (02) :247-254
[4]   Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications [J].
Cattran, DC ;
Pei, Y ;
Greenwood, CMT ;
Ponticelli, C ;
Passerini, P ;
Honkanen, E .
KIDNEY INTERNATIONAL, 1997, 51 (03) :901-907
[5]   A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy [J].
Cheng, IKP ;
Fang, GX ;
Wong, MC ;
Ji, YL ;
Chan, KW ;
Yeung, HWD .
NEPHROLOGY, 1998, 4 (1-2) :19-26
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]  
Donadio JV, 1999, J AM SOC NEPHROL, V10, P1772
[8]   IDIOPATHIC MEMBRANOUS NEPHROPATHY - THE NATURAL-HISTORY OF UNTREATED PATIENTS [J].
DONADIO, JV ;
TORRES, VE ;
VELOSA, JA ;
WAGONER, RD ;
HOLLEY, KE ;
OKAMURA, M ;
ILSTRUP, DM ;
CHU, CP .
KIDNEY INTERNATIONAL, 1988, 33 (03) :708-715
[9]   A CONTROLLED TRIAL OF FISH-OIL IN IGA NEPHROPATHY [J].
DONADIO, JV ;
BERGSTRALH, EJ ;
OFFORD, KP ;
SPENCER, DC ;
HOLLEY, KE .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1194-1199
[10]  
Donadio JV, 2001, J AM SOC NEPHROL, V12, P791, DOI 10.1681/ASN.V124791